Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy

Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy

Triple-negative breast cancer (TNBC) is among the aggressive subtype of breast cancer with a distinct lack of viable treatment strategies and poor clinical outcomes. Anti-PD-1 chemoimmunotherapy (CIT), which leverages the vast array of immunomodulatory effects induced by chemotherapeutic agents to p...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohammed O. Gbadamosi, Elizabeth Molchan, Mariana S. Makarem, Kennedy L. Coleman, Alyssa C. Ohaegbulam, Kathleen H. Streeks
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:OncoImmunology
Subjects:
Chemoimmunomodulation
chemotherapy
immune-checkpoint inhibitors
immunotherapy
triple-negative breast cancer
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2025.2527303
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items